The Topical Nanodelivery of Vismodegib Enhances Its Skin Penetration and Performance <i>In Vitro</i> While Reducing Its Toxicity <i>In Vivo</i>
Vismodegib is a first-in-class inhibitor for advanced basal cell carcinoma treatment. Its daily oral doses present a high distribution volume and several side effects. We evaluated its skin penetration loaded in diverse nanosystems as potential strategies to reduce side effects and drug quantities....
Saved in:
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
Call Number: |
A1234.567 |
---|---|
Copy 1 | Available |